Health Areas › Cardiovascular Diseases
Cardiovascular Diseases
Area 1 in the list of seventeen published by the Saudi National Institute of Health in June 2025. Order follows SNIH's published list: that number is SNIH's own position for the area; it is not a ranking by this site and it says nothing about how much research this area should receive.
This area is matched to research by its subject headings, Cardiovascular Diseases (C14), and to disease burden by the WHO cause-to-area table v0.4. The two line up well enough here for the research-share-to-burden-share ratio to be shown, with the differences named: a close match.
A paper or study can count in more than one area. Areas as published by the Saudi National Institute of Health (SNIH), June 2025, applied to 2021–2025 retrospectively, for description only. A Saudi affiliation is not the same as research on the Saudi population.
Close match. The area and its WHO causes line up well enough to show the research-share-to-burden-share ratio, with the differences named.
Order follows SNIH's published list: area 1 of seventeen.
Coverage Of The Underlying Corpus · 2021–2025
On the same selection, before the area filter. Papers without MeSH terms stay in this coverage line; they are never in any area or in the grey row. It describes the corpus, not how completely this area’s research is captured.
Papers without MeSH terms cannot be assigned to any area, so this profile is never a complete count of the area’s research, and it does not measure how completely that research is captured. Coverage: records captured by the named sources that meet the published eligibility rules; coverage is not exhaustive.
Eligible publications with MeSH terms
60.6%
PubMed with OpenAlex · 2021–2025
Eligible publications matched to any area
41.3%
PubMed with OpenAlex · 2021–2025
The Burden This Area Carries
Burden Share & Research Share
Burden: WHO Global Health Estimates, 2023 · research: 2021–2025
Share of national disease burden
Source: WHO Global Health Estimates, 2023, through the WHO cause-to-area table v0.4. All-age disability-adjusted life years for one named year.
15.8%
WHO · 2023
Research share among MeSH-indexed eligible publications
Eligible publications in this area, 2021–2025, divided by all eligible publications with MeSH terms in the same selection, before the area filter. Shares across the seventeen areas do not sum to 100%.
7.0%
of the eligible publications with MeSH terms · 2021–2025
Research-share-to-burden-share ratio
Shown because this area is a close match. A ratio of 1 means equal shares under these definitions; it does not establish adequate research effort or funding, and it carries no judgement about what the right figure would be.
0.44
Recorded Research
Three Counts, Never One Total
Papers and registrations are counted separately, never added together.
A paper, a clinical trial and an observational registration are different kinds of record, so this area carries three separate counts. They are never added together.
Papers and registrations are different kinds of record. They are counted separately and never added together, anywhere on this site. Counts describe recorded activity; they do not assess quality, benefit or performance.
Registrations are ClinicalTrials.gov records; a listed site doesn't prove recruitment in Saudi Arabia.
Journals that follow ICMJE policy require clinical trials to be registered before enrolment begins, in ClinicalTrials.gov or another accepted registry; observational studies have no such requirement, so registered observational studies are a small, selective part of observational research. These figures count studies recorded in ClinicalTrials.gov; they do not measure total research volume, study completion or financial investment.
Trials and observational studies are those listing a Saudi site. A listed site does not prove that participants were recruited in Saudi Arabia. Withdrawn studies and expanded-access records are not counted.
Publications
PubMed and OpenAlex · research-related papers with a Saudi affiliation carrying Cardiovascular Diseases (C14) · 2021–2025
PubMed with OpenAlex · 2021–2025 provisional
Clinical trials
ClinicalTrials.gov · interventional, listing a Saudi site · 2021–2025
ClinicalTrials.gov · 2021–2025 provisional
Observational studies
ClinicalTrials.gov · observational registrations listing a Saudi site · 2021–2025
ClinicalTrials.gov · 2021–2025 provisional
Research-related papers in this area, by year of earliest publication. The axis starts at zero and ends at 1,000.
Research-related papers in this area, 2021–2025, in the five study groups. The axis starts at zero and ends at 2,000.
Trials in this area, 2021–2025. A trial registered across two phases counts in both. The axis starts at zero and ends at 25.
Trials in this area, 2021–2025, by status as the registry records it on the day ClinicalTrials.gov processed the data. The axis starts at zero and ends at 20. Statuses open largest first.
Observational studies in this area, 2021–2025, by status as the registry records it. The axis starts at zero and ends at 10. Statuses open largest first.
Industry
Industry In This Area
The area's three counts narrowed to industry: research papers coded industry-involved, industry-led clinical trials and industry-led observational studies, each with its share of the area's own count. They are three kinds of record and are never added together.
Industry in papers comes from each paper's own industry code; industry in registrations comes from the lead sponsor. They are different measures of different records and are never combined.
Industry in registrations means a lead sponsor that is a company making or selling health products (drugs, vaccines, biotechnology, devices, diagnostics, health software or medical nutrition), as the industry guide defines it in its section two, or a contract research organisation with such a company listed as collaborator. Hospital groups and other providers that ClinicalTrials.gov labels “industry” are not counted. Withdrawn studies are not counted.
Journals that follow ICMJE policy require clinical trials to be registered before enrolment begins, in ClinicalTrials.gov or another accepted registry; observational studies have no such requirement, so registered observational studies are a small, selective part of observational research. These figures count studies recorded in ClinicalTrials.gov; they do not measure total research volume, study completion or financial investment.
Counts describe recorded activity; they do not measure investment, quality or performance.
Industry involvement in papers is a lower bound.
Industry involvement is identified from the paper's own record and registration; it does not establish financial investment and is a lower bound.
Industry-involved publications
4% of the 2,869 research papers in the area
PubMed with OpenAlex · 2021–2025 provisional
Industry-led clinical trials
38% of the 42 clinical trials in the area
ClinicalTrials.gov · 2021–2025 provisional
Industry-led observational studies
47% of the 19 observational studies in the area
ClinicalTrials.gov · 2021–2025 provisional
Companies
Companies Leading Studies In This Area
Every company credited with at least one industry-led clinical trial or observational study in this area, 2021–2025, with both counts: two counts, never one total. Each study is credited to one company, exactly as the industry-led counts decide it: its lead sponsor or, for a contract research organisation's study, its company collaborator listed in the registration. So the companies' studies add up to the area's industry-led counts. A study in several areas counts in each. Names are shown as registered, with no grouping into parent companies.
There is no rank column. The list opens with the most clinical trials, ties A–Z. Every count above zero opens its records.
Only studies listing a Saudi site are counted. Industry in registrations means a lead sponsor that is a company making or selling health products (drugs, vaccines, biotechnology, devices, diagnostics, health software or medical nutrition), as the industry guide defines it in its section two, or a contract research organisation with such a company listed as collaborator. Hospital groups and other providers that ClinicalTrials.gov labels “industry” are not counted. Withdrawn studies are not counted.
Journals that follow ICMJE policy require clinical trials to be registered before enrolment begins, in ClinicalTrials.gov or another accepted registry; observational studies have no such requirement, so registered observational studies are a small, selective part of observational research. These figures count studies recorded in ClinicalTrials.gov; they do not measure total research volume, study completion or financial investment.
The counts describe registered activity; they do not measure investment, quality or performance.
Showing 2021–2025 provisional
Registrations are ClinicalTrials.gov records; a listed site doesn't prove recruitment in Saudi Arabia.
A listed site does not prove that participants were recruited in Saudi Arabia. Withdrawn studies and expanded-access records are not counted.
| Company | Clinical trials | Observational studies |
|---|---|---|
| AstraZeneca | ||
| Boehringer Ingelheim | 0 | |
| Novartis Pharmaceuticals | 0 | |
| Abbott Medical Devices | ||
| Janssen Research & Development, LLC | 0 | |
| Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 0 | |
| KalVista Pharmaceuticals, Ltd. | 0 | |
| Merck Sharp & Dohme LLC | 0 | |
| Novo Nordisk A/S | 0 | |
| Pharvaris Netherlands B.V. | 0 | |
| AbbVie | 0 | |
| Boston Scientific Corporation | 0 | |
| Elixir Medical Corporation | 0 | |
| Hoffmann-La Roche | 0 | |
| Medtronic | 0 | |
| W.L.Gore & Associates | 0 |
Institutions
Institutions In This Area
Every institution on the approved list with at least one research-related publication, clinical trial or observational study in this area, 2021–2025. Three counts, never one total: a paper, a clinical trial and an observational registration are different kinds of record.
They are counted exactly as on Institutions & Clusters: publications in full; a parent institution's row also counts its units' papers and studies, so rows overlap and are never added together; clinical trials and observational studies count registrations listing the institution as a site, and a listed site does not prove that participants were recruited there. Institutions are named as OpenAlex records them.
There is no rank column. The list opens with the most publications, ties A–Z; the switch orders it by clinical trials, observational studies or A–Z. Every count above zero opens its records. No citation measure is given here.
126 of the area's 2,869 research papers have no Saudi institution identified and count in no institution · PubMed with OpenAlex · 2021–2025 provisional
of
| Institution | Publications | Clinical trials | Observational studies |
|---|---|---|---|
| King Saud University | 0 | ||
| King Abdulaziz University | 0 | 0 | |
| King Faisal Specialist Hospital & Research Centre | |||
| King Saud bin Abdulaziz University for Health Sciences | 0 | 0 | |
| King Khalid University | 0 | 0 | |
| King Abdullah International Medical Research Center | 0 | ||
| Princess Nourah bint Abdulrahman University | 0 | ||
| National Guard Health Affairs | 0 | 0 | |
| Umm al-Qura University | 0 | ||
| Alfaisal University | 0 | 0 | |
| Prince Sattam Bin Abdulaziz University | 0 | ||
| Imam Abdulrahman Bin Faisal University | 0 | ||
| King Abdulaziz Medical City | |||
| Qassim University | 0 | 0 | |
| Jazan University | 0 | 0 | |
| Taif University | 0 | 0 | |
| King Fahd Medical City | |||
| Jouf University | 0 | 0 | |
| King Faisal University | 0 | 0 | |
| University of Tabuk | 0 | 0 | |
| King Saud Medical City | 0 | ||
| Ministry of Health | 0 | 0 | |
| Taibah University | 0 | 0 | |
| University of Ha'il | 0 | 0 | |
| King Fahd Armed Forces Hospital | 0 | ||
| Imam Mohammad ibn Saud Islamic University | 0 | 0 | |
| University of Jeddah | 0 | 0 | |
| Shaqra University | 0 | 0 | |
| Riyadh Armed Forces Hospital | 0 | 0 | |
| King Fahd Hospital of the University | 0 | 0 | |
| Majmaah University | 0 | ||
| University of Bisha | 0 | 0 | |
| King Abdul Aziz University Hospital | 0 | ||
| Batterjee Medical College | 0 | 0 | |
| Sulaiman Al Rajhi Colleges | 0 | 0 | |
| Almaarefa University | 0 | 0 | |
| Najran University | 0 | 0 | |
| Jeddah First Health Cluster | 0 | 0 | |
| King Fahad Specialist Hospital (location not recorded) | 0 | 0 | |
| King Abdullah Medical City | 0 | 0 | |
| King Abdulaziz Hospital (Jeddah First Health Cluster) | 0 | 0 | |
| King Abdullah University of Science and Technology | 0 | 0 | |
| Northern Border University | 0 | 0 | |
| Security Forces Hospital | 0 | 0 | |
| Armed Forces Hospital (location not recorded) | 0 | 0 | |
| International Medical Center in Jeddah | 0 | 0 | |
| Fakeeh College for Medical Sciences | 0 | 0 | |
| Al Baha University | 0 | 0 | |
| Saudi Aramco (Saudi Arabia) | 0 | 0 | |
| Saudi Aramco Medical Services Organization | 0 | 0 | |
| University of Hafr Al-Batin | 0 | 0 | |
| Bugshan Hospital | 0 | 0 | |
| Prince Sultan Military College of Health Sciences | 0 | 0 | |
| King Khalid University Hospital | 0 | 0 | |
| Ibn Sina National College for Medical Studies | 0 | 0 | |
| King Fahad Hospital Jeddah | 0 | 0 | |
| Prince Sultan University | 0 | 0 | |
| Armed Forces Hospital Southern Region | 0 | 0 | |
| King Fahd Military Medical Complex | 0 | 0 | |
| Asir Central Hospital | 0 | 0 | |
| King Khaled Eye Specialist Hospital | 0 | ||
| King Salman Center for Disability Research | 0 | 0 | |
| Ministry of Defense | 0 | 0 | |
| Prince Mohammed bin Abdulaziz Hospital | 0 | 0 | |
| King Abdulaziz City for Science and Technology | 0 | 0 | |
| Riyadh Elm University | 0 | 0 | |
| Saudi Electronic University | 0 | 0 | |
| Saudi Food and Drug Authority | 0 | 0 | |
| Dar Al Uloom University | 0 | 0 | |
| Research and Innovation Institute (location not recorded) | 0 | 0 | |
| Saud Al-babtain Cardiac Centre | 0 | ||
| Soliman Fakeeh Hospital | 0 | 0 | |
| Buraydah Colleges | 0 | 0 | |
| Effat University | 0 | 0 | |
| Mohammed Almana College for Medical Sciences | 0 | 0 | |
| King Fahad Central Hospital (location not recorded) | 0 | 0 | |
| King Fahad Hospital Hufūf | 0 | 0 | |
| Royal Commission for Jubail and Yanbu | 0 | 0 | |
| Maternity and Children's Hospital (location not recorded) | 0 | 0 | |
| Prince Mohammad bin Fahd University | 0 | 0 | |
| East Jeddah Hospital | 0 | 0 | |
| Islamic University of Madinah | 0 | 0 | |
| Saudi Health Council | 0 | 0 | |
| King Khaled Hospital (location not recorded) | 0 | 0 | |
| Saudi Heart Association | 0 | 0 | |
| Dar Al-Hekma University | 0 | 0 | |
| Dhahran Health Center | 0 | 0 | |
| Dr. Samir Abbas Hospital | 0 | 0 | |
| Hera General Hospital | 0 | 0 | |
| Imam Abdulrahman Al Faisal Hospital | 0 | 0 | |
| King Abdulaziz Hospital (location not recorded) | 0 | 0 | |
| Ministry of Education | 0 | 0 | |
| Al Lith General Hospital | 0 | 0 | |
| Al-Ghad International Health Sciences Colleges | 0 | 0 | |
| Al-Thagher General Hospital | 0 | 0 | |
| Arab East Colleges | 0 | 0 | |
| Dammam Central Hospital | 0 | 0 | |
| Eye Center (location not recorded) | 0 | 0 | |
| Fahd bin Sultan University | 0 | 0 | |
| King Abdullah City for Atomic and Renewable Energy | 0 | 0 | |
| King Fahd University of Petroleum and Minerals | 0 | 0 | |
| Magrabi Hospitals and Centers | 0 | 0 | |
| Naif Arab University for Security Sciences | 0 | 0 | |
| Prince Mohammad Bin Salman College of Business and Entrepreneurship | 0 | 0 | |
| Qatif Central Hospital | 0 | 0 | |
| Saudi Commission for Health Specialties | 0 | 0 | |
| University of Business and Technology | 0 | 0 |
Clinical Trials
Clinical Trials By Intervention Type
The area's clinical trials, 2021–2025, by ClinicalTrials.gov's intervention type, with the industry-led part. A trial with several intervention types counts in each, so the bars are never added together and can sum to more than the area's 42 trials. “Other” is the registry's own type; it comes last, as “Not recorded” would. The list opens largest first, ties A–Z. Each count above zero opens its records. Observational studies are not shown by type.
The axis starts at zero and ends at 20.
All trials Industry-led trials
ClinicalTrials.gov · 2021–2025 provisional
National Health Facts · Saudi Arabia
Cardiovascular Diseases: National Health Facts
National health facts checked against their sources: 4 November 2026 to 5 November 2026.
Each card names its source in short; its ⓘ gives the full source. The full view below holds every fact with its full source.
Estimate. Estimated or modelled by its source, not counted directly.
Heart and blood-vessel diseases, including stroke. National figures for all residents unless stated.
At A Glance
About 14,000
deaths from ischaemic heart disease in 2023, the leading cause of death in Saudi Arabia
Estimate WHO · 2023
Estimate WHO Global Health Estimates, 2023 · 2023
34.0%
of adults aged 30–79 have hypertension
Estimate WHO · 2019
Estimate WHO data portal, Saudi Arabia · 2019 · adults 30–79, age-standardised, WHO's modelled estimate (NCD-RisC, 1990–2019)
19.0%
and 25.6% of men and of women with hypertension have it controlled
Estimate NCD-RisC · 2019
Estimate NCD-RisC hypertension data (Lancet 2021), Saudi Arabia file · 2019 · adults 30–79 with hypertension, age-standardised, modelled
Show Health Facts & SourcesHide Health Facts & Sources
Burden
Lost healthy life by condition within this area, 2023 (WHO estimates, WHO causes matched to the area by the project's cause table v0.4). The area's share of national burden appears in the profile's burden comparison lower down. Stroke is also counted under Neurological Diseases, and congenital heart anomalies under Rare and Inherited Diseases; areas overlap, so area shares don't add up to a total. DALYs are the years of healthy life lost to illness, disability or early death.
Share of the area's DALYs
| Series | Share | DALYs | Deaths |
|---|---|---|---|
| Ischaemic heart disease | 46% | 478,267300,150 to 656,383 | 14,2699,456 to 19,741 |
| Hypertensive heart disease | 19% | 196,19981,160 to 311,238 | 7,0514,173 to 11,154 |
| Stroke | 15% | 151,49575,088 to 227,902 | 4,2352,286 to 6,828 |
| Cardiomyopathy, myocarditis, endocarditis | 3% | 33,0578,477 to 57,636 | 882405 to 1,643 |
| Rheumatic heart disease | 1% | 8,6302,554 to 14,707 | 232112 to 431 |
| Other conditions in this area, including congenital heart anomalies | 16% | 162,018 | 3,381 |
Intervals: uncertainty interval · Source: WHO Global Health Estimates, 2023
Key Indicators
Hypertension among adults aged 30–79 is estimated at 34.0% in 2019 (interval 27.1%–41.5%): 36.3% of men and 30.2% of women. The series moved from 34.3% in 2015 to 34.0% in 2019.
Share of people with hypertension, age-standardised; dots are estimates, lines their 95% intervals
Men Women
adults 30–79 with hypertension, age-standardised, modelled · Intervals: 95% uncertainty interval · Source: NCD-RisC hypertension data (Lancet 2021), Saudi Arabia file
| Series | 2015 | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|---|
| Hypertension, adults 30–79 | 34.3% | 34.2% | 34.2% | 34.1% | 34.0% |
adults 30–79, age-standardised, modelled · Source: WHO data portal, Saudi Arabia
Where Sources Differ
The 2019 national survey measured blood pressure; WHO's estimate comes from a model and covers ages 30–79 only.
| Measure | Figure | What it is | Why the figures differ |
|---|---|---|---|
| Hypertension, all adults | 24.5% | ages 18+, age-standardised, World Health Survey 2019Ministry of Health, hypertension treatment coverage and prevalence (World Health Survey 2019) · 2019 · adults 18+, measured, age-standardised | WHO publishes ages 30–79 only; the Ministry of Health's report of the 2019 national survey covers all adults, so the two are not directly comparable. |
Sources Of These Facts
About These Figures
How This Area Is Matched
A paper belongs to this area when any of its subject headings is one of the area's headings or sits beneath it. Registered studies use the same headings, applied to the conditions the registry records. Only records carrying subject headings can be assigned at all, and coverage is reported for every selection.
What This Page Does Not Say
Nothing here assesses quality, benefit or performance, and no figure on it should be read as a target. The research-share-to-burden-share ratio compares two shares; it does not establish that research in this area is too much, too little or correctly aimed. Counts describe what is recorded, which is not the same as what was done.
Where The Figures Come From
Publications from PubMed matched with OpenAlex; trials and observational studies from ClinicalTrials.gov. Area assignment follows the SNIH 17-area research dictionary v1.2; burden follows the WHO cause-to-area table v0.4. Both are published in full on the methods page.
Records Behind This Figure
* Not final: counts for these years usually rise at later updates, as many studies are registered after they start and recent papers are still being added. On this page: trials and publications 2025; observational studies 2024–2025.